论文部分内容阅读
Personalized arid molecular-based cancer treatment depends on biomarkers.Biomarker research and assay development could drive drug discovery, clinical diagnostics, prognostics and treatment decisions.Immunohistochemistry (IHC), which examines protein biomarker expression in combination with tissue morphology, has become more and more important in assays that required using archival formalin-fixed, paraffin embedded (FFPE) tissues.